Ignite Creation Date:
2024-05-06 @ 8:02 PM
Last Modification Date:
2024-10-26 @ 3:19 PM
Study NCT ID:
NCT06239311
Status:
RECRUITING
Last Update Posted:
2024-06-17
First Post:
2024-01-11
Brief Title:
Efficacy and Safety of Methotrexate Versus Placebo in Adults With Atopic Dermatitis
Sponsor:
medac GmbH
Organization:
medac GmbH
Study Overview
Official Title:
A Phase 3 Randomised 2-arm Parallel-group Double-blind Placebo-controlled Trial to Evaluate the Efficacy and Safety of Subcutaneous Methotrexate Versus Placebo in Moderate to Severe Atopic Dermatitis
Status:
RECRUITING
Status Verified Date:
2024-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Atopic dermatitis is an ongoing condition that causes skin irritation redness and itchiness Treatments are usually topical - applied to the skin eg moisturisers or medicated creams - but a wider variety of systemic treatments that target the whole body are needed for those whose condition does not improve with topical treatments Methotrexate a drug approved for similar conditions such as arthritis and psoriasis has been shown to improve atopic dermatitis This randomised controlled clinical trial will investigate how effective
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2023-504443-13-00 | CTIS | None | None |